Inhibikase Therapeutics (IKT) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sutro Biopharma (STRO) has outperformed Inhibikase Therapeutics (IKT) over the past year, gaining 74.5% versus a gain of 19.8%. Inhibikase Therapeutics is the larger company by market cap ($270.7 million vs $243.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IKT | STRO |
|---|---|---|
| Share price | $1.94 | $14.66 |
| Market cap | $270.70M | $243.08M |
| 1-day change | -2.02% | +1.45% |
| YTD return | -5.37% | +26.71% |
| 1-year return | +19.75% | +74.52% |
| 5-year return | — | -92.28% |
| EPS (TTM) | $-0.43 | $-17.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $43.85 |
| 52-week low | $1.33 | $7.15 |
| Distance from 52-week high | -25.67% | -66.57% |
| Average volume | 659.39K | 289.73K |
| Shares outstanding | 139.54M | 16.58M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed IKT by 54.8 percentage points over the past year.
IKT vs STRO FAQ
Which is bigger, Inhibikase Therapeutics or Sutro Biopharma?
Inhibikase Therapeutics (IKT) is larger, with a market capitalization of $270.70M compared with $243.08M for Sutro Biopharma (STRO).
Which stock has performed better over the past year, IKT or STRO?
STRO returned +74.52% over the past 12 months, compared with +19.75% for IKT (price return, excluding dividends). Past performance does not predict future results.
Are Inhibikase Therapeutics and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.